Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Shirin Tavakoli
Institution:
Tehran University of Medical Sciences
Observed institution:
Tehran University of Medical Sciences
ORCID:
0000-0001-8016-6403
Observed ORCID:
0000-0001-8016-6403
OpenAlex ID:
A5044091914
Natural killer cell therapy in hepatocellular carcinoma: a comprehensive review
2025
·
Shirin Tavakoli
, Maryam Samareh-Salavati
, et al.
·
Discover Oncology
·
19
PDF
Prophylactic infusion of donor derived CMV specific T cells for the prevention of CMV reactivation following allogeneic HSCT
2025
·
Maryam Barkhordar
, Maryam Samareh Salavatipour
, et al.
·
Scientific Reports
·
6
PDF
Evaluating the safety and feasibility of allogeneic NK cell infusion in high-risk lymphoma patients post-autologous stem cell transplantation
2025
·
Shirin Tavakoli
, Maryam Samareh-Salavatipour
, et al.
·
Discover Oncology
·
4
PDF
Cell therapy using anti-NKG2A pretreated natural killer cells in patients with hepatocellular carcinoma
2024
·
Shirin Tavakoli
, Maryam Samareh Salavati
, et al.
·
Advanced Pharmaceutical Bulletin
·
4
PDF
Reduced Cish expression by siRNA knockdown in Natural Killer cells promotes anti-tumor effects against gastric cancer cell lines
2025
·
Sahar Khojastehpour
, Azarmidokht Aminazad
, et al.
·
Discover Oncology
·
1
PDF
Evaluating the safety and feasibility of prophylactic third-party NK cell administration in high-risk AML patients post-HSCT
2025
·
Maryam Barkhordar
, Shima Tavoosi
, et al.
·
BMC Cancer
PDF
Safety and feasibility of blockade of NK group-2 member-A receptor in natural killer cells combined with cetuximab antibody in patients with advanced gastric adenocarcinoma
2025
·
Maryam Samareh Salavatipour
, Shirin Tavakoli
, et al.
·
Advanced Pharmaceutical Bulletin
PDF
Show more works
View as search
Works count:
7
Citation count:
34
H-index:
4
I10-index:
1
Year
Topic
Type